These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 810673)

  • 21. [Experiences with aldactone in pediatric cardiology (author's transl)].
    Wimmer M; Bachl G; Schlemmer M; Stiskal A
    Padiatr Padol; 1979; 14(4):363-72. PubMed ID: 530724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of intravenous potassium canrenoate in patients with severe heart failure and digitalis toxicity.
    Cristodorescu R; Puschita M; Deutsch G; Berger E; Luca C
    Med Interne; 1977; 15(1):27-34. PubMed ID: 841250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C; Mantellini R; Fanti P; Sciarra F
    Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical study of verospirone and spironolactone.
    Gãbor G; Bekes M; Polãk G; Rausch J; Gulyãs A
    Ther Hung; 1972; 20(1):36-45. PubMed ID: 5076528
    [No Abstract]   [Full Text] [Related]  

  • 25. [Comparison of the therapeutic efficacy of spironolactone and furosemide in patients with severe congestive heart failure].
    Bednarz B; Cybulski J; Chamiec T
    Pol Merkur Lekarski; 2000 Aug; 9(50):519-21. PubMed ID: 11081314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate.
    Dupont A
    Lancet; 1985 Sep; 2(8457):731. PubMed ID: 2863716
    [No Abstract]   [Full Text] [Related]  

  • 27. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of K-canrenoate in post-surgical treatment of open heart paediatric surgery (author's transl)].
    Capuani A; Bernabei M; Pasque A; Eufrate S
    G Ital Cardiol; 1980; 10(9):1148-55. PubMed ID: 7461364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S; Buch J
    Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Disorders of water and electrolyte equilibrium in liver diseases. Part 3: therapy (author's transl)].
    Kuntz E
    MMW Munch Med Wochenschr; 1982 May; 124(19):465-7. PubMed ID: 6810108
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of canrenoate potassium on intraoperative disturbances of electrolyte equilibrium].
    Eschner J; Fodor L; Ahnefeld FW
    Infusionsther Klin Ernahr; 1976 Apr; 3(2):98-104. PubMed ID: 965083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [False values of blood digoxin in patients with acute and chronic liver disease. Role of canrenoate potassium and comparison of radioimmunologic and immunoenzymatic methods].
    Nardoni A; di Piazza V; Moretti V; Copetti R; Trinco G; Geatti O
    Clin Ter; 1988 May; 125(4):287-90. PubMed ID: 2974364
    [No Abstract]   [Full Text] [Related]  

  • 33. [Brain edema in neurosurgery. Trial with an aldosterone-antagonist (soldactone) (author's transl)].
    Anderes JP; de Tribolet N; Zander E
    Schweiz Rundsch Med Prax; 1977 Aug; 66(32):1020-6. PubMed ID: 556440
    [No Abstract]   [Full Text] [Related]  

  • 34. [New aspects of the use of spironolactone and its association with thiabutazide (per os and in injections) in the treatment of grave cardiac insufficiency].
    Căruntu M; Mihail A
    Med Interna (Bucur); 1974 Feb; 26(2):177-88. PubMed ID: 4828933
    [No Abstract]   [Full Text] [Related]  

  • 35. Spironolactone as a nonspecific treatment for primary aldosteronism.
    Bravo EL; Dustan HP; Tarazi RC
    Circulation; 1973 Sep; 48(3):491-8. PubMed ID: 4726231
    [No Abstract]   [Full Text] [Related]  

  • 36. Spironolactone and canrenoate: different antialdosteronic diuretic agents.
    Gentilini P
    Hepatology; 1991 May; 13(5):999-1000. PubMed ID: 2030004
    [No Abstract]   [Full Text] [Related]  

  • 37. Single-dose i.v. Aldactone for congestive heart failure: a preliminary observation.
    Ceremuzyński L; Budaj A; Michorowski B
    Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):417-21. PubMed ID: 6629545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of potassium canrenoate in cardiosurgery].
    Tufano R; Scopa M; Brando G; Leone D
    Minerva Anestesiol; 1981 Apr; 47(4):149-54. PubMed ID: 7242963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diuresis therapy in hyperaldosteronism].
    Wallnöfer H; Hanusch M
    Wien Med Wochenschr; 1966 Dec; 116(52):1159-64. PubMed ID: 5996768
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
    Costa FV; Borghi C; Mussi A; Ambrosioni E
    Minerva Cardioangiol; 1988 Oct; 36(10):503-7. PubMed ID: 3226562
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.